1 |
HAN Y M, LEE Y J, JANG Y N, et al. Aspirin improves nonalcoholic fatty liver disease and atherosclerosis through regulation of the PPARδ-AMPK-PGC-1α pathway in dyslipidemic conditions[J]. Biomed Res Int, 2020, 2020: 7806860.
|
2 |
GRATTAGLIANO I, DI CIAULA A, BAJ J, et al. Protocols for mitochondria as the target of pharmacological therapy in the context of nonalcoholic fatty liver disease (NAFLD)[J]. Methods Mol Biol, 2021, 2310: 201-246.
|
3 |
YOUNOSSI Z, ANSTEE Q M, MARIETTI M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(1): 11-20.
|
4 |
刘艳如, 温晓华, 高冕, 等. 非肥胖人群血浆致动脉硬化指数与非酒精性脂肪性肝病的相关性[J]. 临床误诊误治, 2021, 34(10): 94-98.
|
5 |
CAI J, ZHANG X J, JI Y X, et al. Nonalcoholic fatty liver disease pandemic fuels the upsurge in cardiovascular diseases[J]. Circ Res, 2020, 126(5): 679-704.
|
6 |
SCICALI R, DI PINO A, URBANO F, et al. Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: a single lipid center real-world experience[J]. Nutr Metab Cardiovasc Dis, 2021, 31(3): 869-879.
|
7 |
马春艳, 徐瑞霞, 姚雨宏, 等. 冠心病患者血浆PCSK9水平与低密度脂蛋白亚组分的相关性研究[J]. 中国分子心脏病学杂志, 2017, 17(4): 2167-2170.
|
8 |
THEOCHARIDOU E, PAPADEMETRIOU M, REKLOU A, et al. The role of PCSK9 in the pathogenesis of non-alcoholic fatty liver disease and the effect of PCSK9 inhibitors[J]. Curr Pharm Des, 2018, 24(31): 3654-3657.
|
9 |
耿妍, 鲁晓岚, 耿燕, 等. 肠道菌群紊乱在大鼠非酒精性脂肪肝中的作用机制[J]. 分子诊断与治疗杂志, 2020, 12(12): 1626-1630.
|
10 |
李滨, 张佳圆, 王凤永, 等. 胆宁片治疗非酒精性脂肪肝临床效果及对血脂、肝功能和肝纤维化的影响[J]. 解放军医药杂志, 2018, 30(10): 93-96.
|
11 |
DEMERS A, SAMAMI S, LAUZIER B, et al. Pcsk9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver [J]. Arterioscler Thromb Vasc Biol, 2015, 35(12): 2517-2525.
|
12 |
LEBEAU P F, BYUN J H, PLATKO K, et al. Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice[J]. JHEP Rep, 2019, 1(6): 418-429.
|
13 |
王娟, 娜丽, 张迎军, 等. 血清TLR4、HMGB1、IL-6与非酒精性脂肪性肝病患者动脉粥样硬化的相关性[J]. 中西医结合肝病杂志, 2021, 31(8): 712-714.
|
14 |
LI M, XU C, SHI J, et al. Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway[J]. Gut, 2018, 67(12): 2169-2180.
|
15 |
DEWIDAR B, KAHL S, PAFILI K, et al. Metabolic liver disease in diabetes-from mechanisms to clinical trials[J]. Metabolism, 2020, 111S: 154299.
|
16 |
PEDERSEN J S, RYGG M O, KRISTIANSEN V B, et al. Nonalcoholic fatty liver disease impairs the liver-alpha cell axis independent of hepatic inflammation and fibrosis[J]. Hepatol Commun, 2020, 4(11): 1610-1623.
|
17 |
MUHAMMAD T, IKRAM M, ULLAH R, et al. Hesperetin, a citrus flavonoid, attenuates LPS-induced neuroinflammation, apoptosis and memory impairments by modulating TLR4/NF-κB signaling[J]. Nutrients, 2019, 11(3): 648.
|
18 |
CHEN M, XING J, PAN D, et al. Chinese herbal medicine mixture 919 syrup alleviates nonalcoholic fatty liver disease in rats by inhibiting the NF-κB pathway[J]. Biomed Pharmacother, 2020, 128: 110286.
|